| Subject: | Duragesic (Fentanyl Transdermal System) - Changes to the Boxed Warning/Warnings, Contraindications, Precautions and Dosage and Administration Sections of the Prescribing Information |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Mon, 18 Jul 2005 - 10:00 am |
| Janssen and the FDA notified healthcare professionals of changes to the BOXED WARNING/WARNINGS, CONTRAINDICATIONS, PRECAUTIONS, and DOSAGE AND ADMINISTRATION sections of the prescribing information for Duragesic.
Duragesic (fentanyl transdermal system) is indicated for management of persistent, moderate to severe chronic pain that 1) requires continuous, around-the-clock opioid administration for an extended period of time, and 2) cannot be managed by other means such as non-steroidal... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
Related MCN Products:
|
|
StayAlert! notifies healthcare customers of all federal and regulatory body legislation changes impacting the healthcare industry, including TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others. StayAlert! complements this with regulatory implementation action plans. StayAlert! serves as a virtual healthcare department, augmenting traditional employee staffed departments and freeing employees to perform other vital functions. The StayAlert! system was designed by healthcare professionals actively working in the healthcare environment, who were faced with attempting to competently provide quality care and services while "doing more with less". StayAlert! provides the answer to efficiently performing a variety of required job components from one centralized virtual location. StayAlert! improves data sharing and communications, thus reducing cost, broadening access and providing a system of documentation and follow-up. |
|
